Recruiting

AcoramidisCardiac Magnetic Resonance and Echocardiography Study With Acoramidis

Sponsor:

Eidos Therapeutics, a BridgeBio company

Code:

NCT07695701

Conditions

Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Amyloidosis

Amyloid Cardiomyopathy

Transthyretin Amyloidosis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Acoramidis (AG10) oral tablet

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-26. This information was provided to ClinicalTrials.gov by Eidos Therapeutics, a BridgeBio company on 2026-07-29.